Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q07817

UPID:
B2CL1_HUMAN

ALTERNATIVE NAMES:
Apoptosis regulator Bcl-X

ALTERNATIVE UPACC:
Q07817; E1P5L6; Q5CZ89; Q5TE65; Q92976

BACKGROUND:
The Bcl-2-like protein 1, with alternative name Apoptosis regulator Bcl-X, is a potent inhibitor of cell death. It plays a significant role in the G2 checkpoint of mitosis and cytokinesis. The protein's ability to regulate mitochondrial ATP availability and synaptic vesicle dynamics underscores its importance in cellular energy management and neural communication. Isoform Bcl-X(L) is involved in inflammation attenuation by impairing NLRP1-inflammasome activation.

THERAPEUTIC SIGNIFICANCE:
Exploring the multifaceted functions of Bcl-2-like protein 1 offers a promising avenue for developing novel therapeutic approaches. Its critical role in apoptosis, cell cycle regulation, and synaptic plasticity makes it a valuable target for drug discovery in oncology and neurodegenerative diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.